Applied Genetic Technologies (Applied Genetic Technologies) Change In Payables And Accrued Expense : $-1.36 Mil (TTM As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Applied Genetic Technologies Change In Payables And Accrued Expense?

Applied Genetic Technologies's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2022 was $0.51 Mil. It means Applied Genetic Technologies's Accounts Payable & Accrued Expense increased by $0.51 Mil from Jun. 2022 to Sep. 2022 .

Applied Genetic Technologies's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2022 was $-1.75 Mil. It means Applied Genetic Technologies's Accounts Payable & Accrued Expense declined by $1.75 Mil from Jun. 2021 to Jun. 2022 .

Applied Genetic Technologies Change In Payables And Accrued Expense Historical Data

The historical data trend for Applied Genetic Technologies's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Genetic Technologies Change In Payables And Accrued Expense Chart

Applied Genetic Technologies Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

2.27

0.93

2.67

4.25

-1.75

Applied Genetic Technologies Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.12	-0.21	-0.94	-0.72	0.51

Applied Genetic Technologies Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.36 Mil.

Applied Genetic Technologies Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Applied Genetic Technologies's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Genetic Technologies (Applied Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Genetic Technologies Corp (NAS:AGTC) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

14193 NW 119th Terrace, Suite 10, Alachua, FL, USA, 32615

Website

https://www.agtc.com

Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.

Executives

Susan Schneider	officer: Chief Medical Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Jonathan I Lieber	officer: Chief Financial Officer	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Stephen W Potter	officer: See Remarks	7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gerald Anthony Reynolds	officer: Chief Accounting Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Susan B. Washer	director, officer: President and CEO	C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Hope Doyley-gay	officer: General Counsel	C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Abraham Scaria	officer: Chief Scientific Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP, 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Yehia Hashad	director	C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Robinson James A. Jr.	director	852 WINTER STREET, WALTHAM MA 02451
William Aliski	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Krol Patrick Johan Hendrik	10 percent owner	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Privium Fund Management B.v.	10 percent owner	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Aescap 2.0 Stichting	10 percent owner	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Inspirational Visions B.v.	10 percent owner	C/O PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, 2333 CK LEIDEN P7 2333
Brian Krex	officer: General Counsel	C/O AGTC, 14193 NW 119TH TERRACE, SUITE #10, ALACHUA FL 32615